Targeted integration of foreign DNA into a defined locus on chromosome 19 in K562 cells using AAV-derived components.
Targeted integration of foreign DNA is ideal for gene therapy, particularly when target cells such as hematopoietic cells actively divide and proliferate. Adeno-associated virus (AAV) has been shown to integrate its genome into a defined locus, AAVS1 (19q13.3-qter). The inverted terminal repeat (ITR) and Rep proteins are responsible for this site-specific integration, and a system has been developed that delivers a gene preferentially into AAVS1 by using these components of AAV. We examined whether this system could be applied to gene transfer into K562 cells. Two rep expression plasmids were tested, 1 driven by the cytomegalovirus (CMV) promoter (pCMVR78) and the other under the translational control of an internal ribosome entry site (pMGiR78) with mouse mammary tumor virus promoter. K562 cells were cotransfected with a rep plasmid and a plasmid containing a neo gene flanked by the ITRs. G418-resistant clones were isolated and analyzed by Southern blot analysis and fluorescence in situ hybridization (FISH). Southern blot analysis suggested AAVS1-specific integration of the neo gene in 6 (35%) of 17 clones when K562 cells were transfected with pMGiR78 by lipofection. FISH located the neo gene on chromosome 19 in 5 of these 6 clones (29%). Eight (32%) of 25 clones obtained by electroporation with pCMVR78 had the neo gene at AAVS1, according to Southern blot analysis, and 4 of these 8 clones (16%) were positive according to FISH analysis. These results suggest that site-specific integration of foreign DNA can be achieved at a significantly high rate in human hematopoietic cells using the AAV components.
Kogure
Katsuhiro
K
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi.|CREST, Japan Science and Technology Corporation, Tochigi.
Urabe
Masashi
M
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi.|CREST, Japan Science and Technology Corporation, Tochigi.
Mizukami
Hiroaki
H
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi.|CREST, Japan Science and Technology Corporation, Tochigi.
Kume
Akihiro
A
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi.|CREST, Japan Science and Technology Corporation, Tochigi.
Sato
Yuko
Y
Department of Intractable Diseases, Research Institute, International Medical Center of Japan, Tokyo, Japan.
Monahan
John
J
Avigen, Inc., Alameda, California, USA.
Ozawa
Keiya
K
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi. kozawa@ms.jichi.ac.jp.|CREST, Japan Science and Technology Corporation, Tochigi. kozawa@ms.jichi.ac.jp.|Division of Hematology, Department of Medicine, Jichi Medical School, Tochigi, Japan. kozawa@ms.jichi.ac.jp.|Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, 3311-1 Yakushiji, Minami-kawachi, 329-0498, Tochigi, Japan. kozawa@ms.jichi.ac.jp.
D002888:Chromosomes, Human, Pair 19 / Q000235:genetics* / Q000821:virology; D004279:DNA, Viral / Q000235:genetics; D000229:Dependovirus / Q000235:genetics*; D005822:Genetic Vectors; D006412:Hematopoietic Stem Cells; D006801:Humans; D020014:K562 Cells; D014162:Transfection; D016662:Virus Integration / Q000235:genetics*
D004279:DNA, Viral